View of FIRST-LINE TREATMENT OUTCOMES OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA: SINGLE-CENTER REAL-WORLD DATA FROM VIETNAM, FROM 2020 TO 2026

Return to Article Details FIRST-LINE TREATMENT OUTCOMES OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA: SINGLE-CENTER REAL-WORLD DATA FROM VIETNAM, FROM 2020 TO 2026 Download Download PDF